ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
ANIP has been the topic of a number of other research reports. Leerink Partnrs raised ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Truist Financial upped their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler initiated coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They issued an “overweight” rating and a $68.00 target price on the stock. Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $77.71.
View Our Latest Stock Analysis on ANIP
ANI Pharmaceuticals Stock Performance
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The business had revenue of $148.30 million for the quarter, compared to the consensus estimate of $144.37 million. During the same quarter in the prior year, the firm posted $1.05 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, sell-side analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.
Insider Transactions at ANI Pharmaceuticals
In related news, CFO Stephen P. Carey sold 7,500 shares of the company’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares in the company, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 42,381 shares of company stock valued at $2,441,556. 12.70% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On ANI Pharmaceuticals
A number of large investors have recently bought and sold shares of ANIP. Thrivent Financial for Lutherans lifted its position in ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after acquiring an additional 299 shares during the last quarter. Louisiana State Employees Retirement System increased its position in shares of ANI Pharmaceuticals by 3.9% during the third quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock worth $477,000 after purchasing an additional 300 shares in the last quarter. Exchange Traded Concepts LLC increased its position in shares of ANI Pharmaceuticals by 2.6% during the fourth quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after purchasing an additional 310 shares in the last quarter. New York State Teachers Retirement System lifted its holdings in shares of ANI Pharmaceuticals by 1.7% during the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after purchasing an additional 394 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after purchasing an additional 412 shares in the last quarter. Institutional investors own 76.05% of the company’s stock.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Stories
- Five stocks we like better than ANI Pharmaceuticals
- Best Stocks Under $5.00
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Airline Stocks – Top Airline Stocks to Buy Now
- 3 Steel Stocks Soaring After Tariff Announcements
- 5 Top Rated Dividend Stocks to Consider
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.